[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
Alban
Susanne
S
Pharmazeutisches Institut, Christian-Albrechts-Universität, Gutenbergstr. 76, 24118 Kiel. salban@pharmazie.uni-kiel.de
D000818:Animals; D001711:Biotransformation; D000077144:Clopidogrel; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride; D011355:Prodrugs; D058919:Purinergic P2 Receptor Antagonists; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D013876:Thiophenes / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; D058919:Purinergic P2 Receptor Antagonists; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine